Modeling the impact of CDK4 / 6 inhibitors on reducing cancer mortality
Background. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (abemaciclib, palbociclib, ribociclib) plus aromatase inhibitors (AI) are the modern standard-of-care of the first-line treatment of hormone-dependent (HR+) HER2-negative (HER2–) advanced breast cancer (ABC).Aim. To evaluate the effects of...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2025-05-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/1348 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!